Novo Nordisk A/S (NYSE:NVO) Releases Earnings Results, Beats Expectations By $0.03 EPS

Novo Nordisk A/S (NYSE:NVO) issued its quarterly earnings results on Wednesday. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.03, Zacks reports. Novo Nordisk A/S had a net margin of 35.03% and a return on equity of 86.32%. Novo Nordisk A/S updated its FY 2025 guidance to EPS.

Novo Nordisk A/S Trading Up 4.9 %

NVO stock traded up $4.05 during midday trading on Wednesday, reaching $86.67. The company’s stock had a trading volume of 9,056,927 shares, compared to its average volume of 9,280,718. The stock has a fifty day simple moving average of $92.65 and a two-hundred day simple moving average of $112.19. The firm has a market capitalization of $388.95 billion, a price-to-earnings ratio of 28.05, a PEG ratio of 0.93 and a beta of 0.45. Novo Nordisk A/S has a 1 year low of $78.17 and a 1 year high of $148.15. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94.

Analyst Ratings Changes

A number of analysts have commented on the company. BMO Capital Markets reduced their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Finally, Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.